New hope for teens with severe asthma? dupilumab under the microscope

NCT ID NCT05070663

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 105 teenagers with severe uncontrolled asthma who were starting treatment with dupilumab (Dupixent). Researchers tracked their asthma control, flare-ups, and safety over one year. The goal was to see if this medication helps teens manage their condition better in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dupilumab (Dupixent)

What this could lead to

If successful, this could show that dupilumab helps teenagers with severe asthma breathe better and have fewer attacks.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only follows 105 teens for one year, and asthma can vary widely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational site France

    France, France